Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy

In the muscle invasive bladder cancer (MIBC) standard of care treatment only patients presenting a major pathological tumor response are more likely to show the established modest 5% absolute survival benefit at 5 years after cisplatin-based neoadjuvant chemotherapy (NAC). To overcome the drawbacks...

Descripción completa

Detalles Bibliográficos
Autores principales: Ossick, Marina Vian, Ferrari, Karen Linares, Nunes-Silva, Igor, Denardi, Fernandes, Reis, Leonardo Oliveira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011207/
https://www.ncbi.nlm.nih.gov/pubmed/32049187
http://dx.doi.org/10.1590/s0102-865020190120000007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011207/
https://www.ncbi.nlm.nih.gov/pubmed/32049187
http://dx.doi.org/10.1590/s0102-865020190120000007

Ejemplares similares